Ribociclib And Endocrine Treatment of Physician's Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast Cancer

ClinicalTrials.gov ID: NCT05467891

Public ClinicalTrials.gov record NCT05467891. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Sep 5, 2026, 10:06 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase II Study of Ribociclib And Endocrine Treatment of Physician's Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast Cancer

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This is an open label, multicenter, single arm phase II study to evaluate the efficacy and safety of ribociclib and ET in patients with locoregional recurrence of HR-positive, HER2-negative breast cancer.

Study identification

NCT ID: NCT05467891
Recruitment status: Recruiting
Study type: Interventional
Phase: Phase 2
Lead sponsor: Oana Danciu; Other
Enrollment: 200 participants

Conditions and interventions

Conditions

Interventions

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Sep 12, 2022
Primary completion: Aug 14, 2028
Completion: Aug 14, 2029
Last update posted: Jul 15, 2026

2022 – 2029

United States locations

U.S. sites: 21
U.S. states: 19
U.S. cities: 21

Facility	City	State	ZIP	Site status
University of Alabama at Birmingham	Birmingham	Alabama	35294	Recruiting
University of Arizona	Phoenix	Arizona	85004	Recruiting
Georgetown University	Washington D.C.	District of Columbia	20057	Recruiting
Orlando Health Cancer Institute	Orlando	Florida	32806	Active, not recruiting
University of Illinois Cancer Center	Chicago	Illinois	60612	Recruiting
Parkview Research Center	Fort Wayne	Indiana	46845	Recruiting
University of Iowa Hospitals and Clinics	Iowa City	Iowa	52242	Recruiting
Tufts Medical Center	Boston	Massachusetts	02111	Recruiting
University of Michigan Health System	Ann Arbor	Michigan	48109	Recruiting
University of Michigan Health-West	Wyoming	Michigan	49519	Terminated
University of Nebraska Medical Center	Omaha	Nebraska	68198	Recruiting
Rutgers Cancer Institute of New Jersey	New Brunswick	New Jersey	08903	Recruiting
University of New Mexico Comprehensive Cancer Center	Albuquerque	New Mexico	87102	Recruiting
New York University Clinical Cancer Center	New York	New York	10016	Recruiting
Ohio State University Comprehensive Cancer Center	Columbus	Ohio	43210	Recruiting
Providence Portland Medical Center	Portland	Oregon	97213	Recruiting
Penn State Cancer Institute	Hershey	Pennsylvania	17033	Recruiting
Medical University of South Carolina	Charleston	South Carolina	29425	Recruiting
University of Virginia Health System	Charlottesville	Virginia	22908	Recruiting
Virginia Commonwealth University	Richmond	Virginia	23298	Recruiting
University of Wisconsin	Madison	Wisconsin	53705	Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT05467891, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Jul 15, 2026 · Synced Sep 5, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT05467891 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →